OraSure Technologies, Inc. (NASDAQ:OSUR) Director Mara G. Aspinall purchased 5,000 shares of the business’s stock in a transaction on Tuesday, November 7th. The stock was bought at an average cost of $14.23 per share, with a total value of $71,150.00. Following the purchase, the director now owns 5,000 shares in the company, valued at $71,150. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

OraSure Technologies, Inc. (NASDAQ OSUR) traded up $0.89 during mid-day trading on Thursday, reaching $14.33. 1,058,755 shares of the company’s stock were exchanged, compared to its average volume of 866,968. OraSure Technologies, Inc. has a fifty-two week low of $7.71 and a fifty-two week high of $23.01. The stock has a market cap of $823.51, a PE ratio of 26.64, a PEG ratio of 2.66 and a beta of 1.39.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported $0.09 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.09. OraSure Technologies had a net margin of 20.48% and a return on equity of 14.12%. The company had revenue of $42.30 million during the quarter, compared to analysts’ expectations of $40.87 million. During the same quarter in the prior year, the company earned $0.11 EPS. The firm’s revenue was up 31.0% on a year-over-year basis. analysts anticipate that OraSure Technologies, Inc. will post 0.42 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “OraSure Technologies, Inc. (OSUR) Director Purchases $71,150.00 in Stock” was originally reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/11/09/orasure-technologies-inc-osur-director-purchases-71150-00-in-stock.html.

Institutional investors have recently made changes to their positions in the company. First Mercantile Trust Co. purchased a new stake in shares of OraSure Technologies in the 2nd quarter valued at $104,000. Pinebridge Investments L.P. purchased a new stake in shares of OraSure Technologies in the 2nd quarter valued at $131,000. Victory Capital Management Inc. boosted its stake in shares of OraSure Technologies by 17.6% in the 2nd quarter. Victory Capital Management Inc. now owns 9,070 shares of the medical instruments supplier’s stock valued at $157,000 after purchasing an additional 1,360 shares in the last quarter. Profund Advisors LLC boosted its stake in shares of OraSure Technologies by 2.8% in the 2nd quarter. Profund Advisors LLC now owns 10,903 shares of the medical instruments supplier’s stock valued at $188,000 after purchasing an additional 293 shares in the last quarter. Finally, ETRADE Capital Management LLC purchased a new stake in shares of OraSure Technologies in the 2nd quarter valued at $193,000. 92.56% of the stock is owned by institutional investors.

A number of research firms have commented on OSUR. Zacks Investment Research cut shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, October 4th. Jefferies Group LLC reissued a “buy” rating and issued a $20.00 price target on shares of OraSure Technologies in a research note on Tuesday, September 12th. Canaccord Genuity reissued a “buy” rating and issued a $22.00 price target on shares of OraSure Technologies in a research note on Tuesday, September 19th. Finally, BidaskClub cut shares of OraSure Technologies from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 24th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $18.21.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Insider Buying and Selling by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.